A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19)

Ming Zhong, Aijun Sun, Ting Xiao, Ge Yao, Ling Sang, Xia Zheng, Jinyan Zhang, Xuejuan Jin, Lei Xu, Wenlong Yang, Peng Wang, Kai Hu, Dingyu Zhang, Junbo GemedRxiv 2020 · DOI

Abstract

This randomized, single-blind, group-sequential trial evaluated the clinical efficacy and safety of α-Lipoic acid (ALA) in critically ill patients with COVID-19. Seventeen patients were enrolled and randomized to receive either 1200 mg/day of intravenous ALA plus standard care or a placebo plus standard care for 7 days. The primary outcome was the Sequential Organ Failure Assessment (SOFA) score, and the secondary outcome was 30-day all-cause mortality. Results indicated that the ALA group experienced a lower increase in SOFA scores and a reduced 30-day mortality rate (37.5% vs. 77.8%, p=0.09) compared to the placebo group. While limited by a small sample size, the findings suggest that ALA may mitigate organ dysfunction and improve survival in severe COVID-19 cases.

Introduction

In the early stages of the COVID-19 pandemic, clinicians identified "cytokine release syndrome" (CRS) and excessive production of reactive oxygen species (ROS) as primary drivers of severe disease. This systemic inflammatory response often leads to diffuse alveolar damage and multi-organ failure. α-Lipoic acid (ALA) is a potent antioxidant known to reduce systemic inflammation in conditions like acute coronary syndrome and organ transplantation. This study sought to determine if ALA could counteract the oxidative stress and inflammatory storm associated with SARS-CoV-2 to improve patient prognosis.

Methods

The trial was conducted at JinYinTan Hospital in Wuhan, China, between February and March 2020.

  • Participants: 17 critically ill COVID-19 patients were enrolled.
  • Intervention: Patients were randomized 1:1 to receive 1200 mg/day of ALA via intravenous infusion for 7 days or an equal volume of saline (placebo), both in addition to standard care.
  • Blinding: The study was single-blind; outcome adjudicators were blinded to treatment assignments.
  • Endpoints: The primary endpoint was the change in SOFA score over 7 days. The secondary endpoint was all-cause mortality at 30 days.
CONSORT Flow Diagram

Results

Organ Failure Progression

At baseline, SOFA scores were similar between groups. Over the 7-day treatment period, the average SOFA score in the placebo group rose from 4.3 to 6.0 (a 1.7-point increase). In contrast, the ALA group remained relatively stable, with scores rising only from 3.8 to 4.0 (a 0.2-point increase). Although the trend favored the ALA group, the difference did not reach statistical significance (p=0.36) due to the small cohort.

SOFA Score Progression

Mortality and Safety

The 30-day all-cause mortality was notably lower in the ALA group (3/8 patients, 37.5%) compared to the placebo group (7/9 patients, 77.8%). This result achieved borderline statistical significance (p=0.09). Importantly, no unexpected drug-related adverse events were reported, indicating that high-dose IV ALA was well-tolerated in this critically ill population.

Discussion and Limitations

The findings suggest that ALA may stabilize organ function and potentially reduce mortality in critically ill COVID-19 patients by mitigating oxidative stress. However, the study's primary limitation is its extremely small sample size ($N=17$), which resulted from the successful control of the epidemic in Wuhan during the trial period. Additionally, the single-blind design and the potential for confounding secondary infections must be considered. While these results are promising, they serve as a signal for larger, multi-center clinical trials to validate the therapeutic role of ALA in severe viral pneumonia.

Summary updated

Abstract

Abstract Object To evaluate the clinical efficacy and safety of α-Lipoic acid (ALA) for critically ill patients with coronavirus disease 2019 (COVID-19). Methods A randomized, single-blind, group sequential, active-controlled trial was performed at JinYinTan Hospital, Wuhan, China. Between February 2020 and March 2020, 17 patients with critically ill COVID-19 were enrolled in our study. Eligible patients were randomly assigned in a 1:1 ratio to receive either ALA (1200 mg/d, intravenous infusion) once daily plus standard care or standard care plus equal volume saline infusion (placebo) for 7 days. All patients were monitored within the 7 days therapy and followed up to day 30 after therapy. The primary outcome of this study was the Sequential Organ Failure Estimate (SOFA) score, and the secondary outcome was the all-cause mortality within 30 days. Result Nine patients were randomized to placebo group and 8 patients were randomized to ALA group. SOFA score was similar at baseline, increased from 4.3 to 6.0 in the placebo group and increased from 3.8 to 4.0 in the ALA group (P=0.36) after 7 days. The 30-day all-cause mortality tended to be lower in the ALA group (3/8, 37.5%) compared to that in the placebo group (7/9, 77.8%, P=0.09). Conclusion In our study, ALA use is associated with lower SOFA score increase and lower 30-day all-cause mortality as compared with the placebo group. Although the mortality rate was two-folds higher in placebo group than in ALA group, only borderline statistical difference was evidenced due to the limited patient number. Future studies with larger patient cohort are warranted to validate the role of ALA in critically ill patients with COVID-19.
BibTeX
@misc{zhong2020randomized,
  author = {Ming Zhong and Aijun Sun and Ting Xiao and Ge Yao and Ling Sang and Xia Zheng and Jinyan Zhang and Xuejuan Jin and Lei Xu and Wenlong Yang and Peng Wang and Kai Hu and Dingyu Zhang and Junbo Ge},
  title = {{A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19)}},
  year = {2020},
  doi = {10.1101/2020.04.15.20066266},
  howpublished = {medRxiv},
}
Figure